CV Sciences, Inc. (OTCQB:CVSI), a San Diego-based company specializing in hemp extracts, nutraceuticals and plant-based foods announced its financial results Tuesday for the quarter ended March 31, 2024. The company reported a slight decline in its first-quarter revenue, generating $4 million compared to $4.1 million in the same quarter last year.  Q1 2024 Financial Highlights Revenue was $4 million, compared to $4.1 million for Q1 2023. Net loss was $0.6 million, compared to a net income of $5.7 million for the same quarter last year. Adjusted EBITDA loss was $0.5 million, compared to the loss of $0.2 million for Q1 2023. Gross profit was $1.9 million, compared to the $1.8 million for the same quarter last year. Despite the revenue decline, the company experienced a sequential increase from $3.8 million in the last quarter of 2023. The company’s gross margin improved significantly, recording 46.3% in Q1 2024, up from 43.0% in Q1 2023. Stay ahead in the cannabis industry by joining industry leaders and experts at the upcoming Benzinga Cannabis Capital Conference in Chicago on Oct. 8-9.